0
Reata Pharmaceuticals, Inc. Banner Image

Reata Pharmaceuticals, Inc. has reached its limit for free report views

Work for Reata Pharmaceuticals, Inc.? Upgrade Your Profile and unlock all your annual reports.

Reata Pharmaceuticals, Inc.

  • Ticker RETA
    Exchange NASDAQ More
  • Industry Biotechnology More
  • Sector Healthcare More
Reata Pharmaceuticals, Inc. Logo Image
  • 201-500 Employees
  • Based in Plano, Texas
Reata is a clinical-stage biopharmaceutical company that develops novel therapeutics for patients with serious or life-threatening diseases by targeting molecular pathways involved in the regulation of cellular metabolism and inflammation. Reata’s two most advanced clinical candidates, bardoxolone methyl (“bardoxolone”) and omaveloxolone, target the important transcription factor Nrf2 thatMore promotes the resolution of inflammation by restoring mitochondrial function, reducing oxidative stress, and inhibiting pro-inflammatory signaling. Bardoxolone and omaveloxolone are investigational drugs, and their safety and efficacy have not been established by any agency.
Reata Pharmaceuticals, Inc.

Most Recent Annual Report

Reata Pharmaceuticals, Inc. MOST RECENT 2019 Annual Report and Form 10K

Report Locked. Reata Pharmaceuticals, Inc. has reached its limit for free report views.

Older/Archived Annual Reports